Home / Letter From The Editor / Aug. 7, 2021

Aug. 7, 2021

Aug 7, 2021

There has been a lot of clamor over the introduction of Wegovy for weight loss. The GLP-1 mimetic had such a huge introduction that supply was not able to keep up with demand. This is a double strength Ozempic product and looks to help patients with obesity as well as diabetes patients. Does this mean that if we double the dose of drugs like the SGLT-2 inhibitors, we will get extra weight loss as well?

It is likely those studies are going on right now as our intern Kornelia Ilias, Pharm.D. Candidate, Creighton University School of Pharmacy, found some new evidence that in certain populations the SGLT-2 inhibitors cause more weight loss than the GLP-1 mimetics. Click on her Laterpay article to find out who these drugs worked best for.




We can make a difference!


Dave Joffe